A request for approval for Olumiant to treat lupus has been withdrawn, and the manufacturers expect the FDA to reject an atopic dermatitis approval request in the face of growing…
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.
A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.
The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as…
A federal judge has thrown out plaintiffs' expert testimony in Viagra and Cialis melanoma lawsuits, pausing, and potentially ending, the litigation.
A bellwether schedule and other items will be discussed at a Viagra litigation status conference next week.
A consumer watchdog group called on FDA advisors to recommend that the agency reject approval for a new Eli Lilly arthritis drug which some data indicates could increase the risk…
Pfizer and Eli Lilly face more than 650 Viagra and Cialis lawsuit filed by men who say the erectile dysfunction drugs caused the development or rapid spread of melanoma.
Following a defense verdict in an AndroGel lawsuit trial, the settlement of a number of Eli Lilly claims, and another case vacated this week just before trial, the court overseeing…
